Drug Research
Drug Discovery & Development

Drug Discovery & Development

Convelo Therapeutics to develop new regenerative medicines for neurological disease characterized by loss of myelin Convelo Therapeutics has launched from stealth mode with a mission to discover and develop a new class of medicines that regenerate the protective myelin coating around nerve cells that is lost in a wide array of neurological diseases, including multiple sclerosis (MS).
Drug Research > Drug Discovery & Development > News
BMS, Tsinghua University collaborate to discover therapeutic agents for autoimmune diseases Bristol-Myers Squibb (BMS) has entered into a collaboration with Tsinghua University to discover therapeutic agents against novel targets for autoimmune diseases and cancers.
Drug Research > Drug Discovery & Development > News Immunomedics, AstraZeneca collaborate in first-line triple-negative breast and urothelial cancers By PBR Staff Writer
Immunomedics has entered into a clinical collaboration with AstraZeneca and its global biologics research and development arm MedImmune in first-line triple-negative breast and urothelial cancers.
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
Convelo Therapeutics to develop new regenerative medicines for neurological disease characterized by loss of myelin
Convelo Therapeutics has launched from stealth mode with a mission to discover and develop a new class of medicines that regenerate the protective myelin coating around nerve cells that is lost in a wide array of neurological diseases, including multiple sclerosis (MS).
Drug Research > Drug Discovery & Development > News
BMS, Tsinghua University collaborate to discover therapeutic agents for autoimmune diseases
Bristol-Myers Squibb (BMS) has entered into a collaboration with Tsinghua University to discover therapeutic agents against novel targets for autoimmune diseases and cancers.
Drug Research > Drug Discovery & Development > News
Immunomedics, AstraZeneca collaborate in first-line triple-negative breast and urothelial cancers
By PBR Staff Writer
Immunomedics has entered into a clinical collaboration with AstraZeneca and its global biologics research and development arm MedImmune in first-line triple-negative breast and urothelial cancers.
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests